The global contraceptive devices market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 6.2% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Contraceptive devices refer to various birth control tools used for preventing pregnancies and sexually transmitted diseases (STDs), such as human immunodeficiency virus (HIV) infection. Some of the commonly used contraceptive devices include condoms, diaphragms, cervical caps, sponges, vaginal rings, subdermal implants and intrauterine devices (IUD). These devices are customized for male and female user and usually contain spermicides to chemically neutralize the sperms. Certain devices also act as a physical barrier to inhibit the sperm from coming in contact with the uterus, thereby preventing insemination and minimizing the risks of infections.
The increasing prevalence of STDs, such as gonorrhea, chlamydia, trichomoniasis, hepatitis B and HIV/AIDS, across the globe represents one of the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available alternatives for preventing unexpected pregnancies is providing a thrust to the market growth. Governments of various developed and developing nations are also implementing campaigns to spread awareness and encourage the use of effective contraceptive devices, especially in rural areas, for population management and preventing the spread of STDs. This has resulted in a significant increase in the demand for easy to use, removable and cost-effective contraceptives. In line with this, various product innovations, such as the development of non-hormonal diaphragms and medium-term vaginal rings, are anticipated to drive the market further. Product manufacturers are largely investing in extensive research and development (R&D) activities to develop variants with higher efficacy and minimal side-effects on long-term use. Other factors, including increasing consumer inclination towards delayed pregnancies, along with rising healthcare expenditures of the individuals, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global contraceptive devices market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, device type, end user and distribution channel.
Breakup by Device Type:
Breakup by End User:
Breakup by Distribution Channel:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc, Bayer Healthcare, Church & Dwight Co. Inc., Cooper Surgical Inc., Merck & Co., Mylan Laboratories, Pfizer Inc., Reckitt Benckiser, Teva Pharmaceutical Industries Ltd. and The Female Health Company.
|Base Year of the Analysis||2020|
|Segment Coverage||Device Type, End User, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Allergan Plc, Bayer Healthcare, Church & Dwight Co. Inc., Cooper Surgical Inc., Merck & Co., Mylan Laboratories, Pfizer Inc., Reckitt Benckiser, Teva Pharmaceutical Industries Ltd. and The Female Health Company|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at